The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Oxidative phosphorylation as a potential therapeutic target for cancer therapy
Open accessAbstract
In contrast to prior belief, cancer cells require oxidative phosphorylation (OXPHOS) to strive, and exacerbated OXPHOS dependency frequently characterizes cancer stem cells, as well as primary or acquired resistance against chemotherapy or tyrosine kinase inhibitors. A growing arsenal of therapeutic agents is being designed to suppress the transfer of mitochondria from stromal to malignant cells, to interfere with mitochondrial biogenesis, to directly inhibit respiratory chain complexes, or to disrupt mitochondrial function in other ways. For the experimental treatment of cancers, OXPHOS inhibitors can be advantageously combined with tyrosine kinase inhibitors, as well as with other strategies to inhibit glycolysis, thereby causing a lethal energy crisis. Unfortunately, most of the preclinical data arguing in favor of OXPHOS inhibition have been obtained in xenograft models, in which human cancer cells are implanted in immunodeficient mice. Future studies on OXPHOS inhibitors should elaborate optimal treatment schedules and combination regimens that stimulate—or at least are compatible with—anticancer immune responses for long‐term tumor control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
Self-citationTransfer of mitochondria from astrocytes to neurons after stroke
Hayakawa, K., Esposito, E., Wang, X., Terasaki, Y., Liu, Y., Xing, C., Ji, X., & Lo, E. H. (2016) · Nature · doi:10.1038/nature18928 · Cited by 1,423
Bax and Adenine Nucleotide Translocator Cooperate in the Mitochondrial Control of Apoptosis
Marzo, I., Brenner, C., Zamzami, N., Jürgensmeier, J. M., Susin, S. A., Vieira, H. L. A., Prévost, M.-C., Xie, Z., Matsuyama, S., Reed, J. C., et al. (1998) · Science · doi:10.1126/science.281.5385.2027 · Cited by 1,168
Self-citationTargeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971
An inhibitor of oxidative phosphorylation exploits cancer vulnerability
Molina, J. R., Sun, Y., Protopopova, M., Gera, S., Bandi, M., Bristow, C., McAfoos, T., Morlacchi, P., Ackroyd, J., Agip, A.-N. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0052-4 · Cited by 928
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
Haq, R., Shoag, J., Andreu-Perez, P., Yokoyama, S., Edelman, H., Rowe, G. C., Frederick, D. T., Hurley, A. D., Nellore, A., Kung, A. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.003 · Cited by 818
Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth
Hitosugi, T., Kang, S., Vander Heiden, M. G., Chung, T.-W., Elf, S., Lythgoe, K., Dong, S., Lonial, S., Wang, X., Chen, G. Z., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000431 · Cited by 784
Pollyea, D. A., Stevens, B. M., Jones, C. L., Winters, A., Pei, S., Minhajuddin, M., D’Alessandro, A., Culp-Hill, R., Riemondy, K. A., Gillen, A. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0233-1 · Cited by 778 · cited 1×
“This combination (but neither of the single agent) caused inhibition of complex II indirectly through a reduced glutathionylation of succinate dehydrogenase, and this OXPHOS inhibition preferentially affected AML stem cells.(47) This example illustrates the possibility to inhibit OXPHOS indirectly through pharmacologi…”
BackgroundVazquez, F., Lim, J.-H., Chim, H., Bhalla, K., Girnun, G., Pierce, K., Clish, C. B., Granter, S. R., Widlund, H. R., Spiegelman, B. M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.020 · Cited by 715
Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma
Shi, Y., Lim, S. K., Liang, Q., Iyer, S. V., Wang, H.-Y., Wang, Z., Xie, X., Sun, D., Chen, Y.-J., Tabar, V., et al. (2019) · Nature · doi:10.1038/s41586-019-0993-x · Cited by 325 · cited 2×
“Gboxin is a compound that enriches in mitochondria driven by ΔΨm and then acts as an inhibitor of the F0F1 ATP synthase (respiratory chain complex V), causing a transient ΔΨm hyperpolarization and a bioenergetic crisis.(38) Interestingly, nontransformed cells are less sensitive to gboxin than glioblastoma cells, and t…”
Background
Cited by
The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma
Goenka, A., Tiek, D., Song, X., Huang, T., Hu, B., & Cheng, S.-Y. (2021) · Cells · doi:10.3390/cells10030484 · Cited by 169
OXPHOS inhibitors, metabolism and targeted therapies in cancer
Cadassou, O., & Jordheim, L. P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115531 · Cited by 59
In situ metabolic Characterisation of Breast Cancer and its Potential Impact on Therapy
Petővári, G., Dankó, T., Tőkés, A.-M., Vetlényi, E., Krencz, I., Raffay, R., Hajdu, M., Sztankovics, D., Németh, K., Vellai-Takács, K., et al. (2020) · Cancers · doi:10.3390/cancers12092492 · Cited by 16
Metadata
- Authors
- Sica, V., Bravo‐San Pedro, J. M., Stoll, G., & Kroemer, G.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2019-09-11
- Volume
- 146
- Issue
- 1
- Pages
- 10-17
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2968141411
- Cited by
- 209
- References
- 15
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oxidative phosphorylation as a potential therapeutic target for cancer therapy. https://app.cochat.ai/papers/10.1002/ijc.32616
- The paper
- Sica, V., Bravo‐San Pedro, J. M., Stoll, G., & Kroemer, G. (2020). Oxidative phosphorylation as a potential therapeutic target for cancer therapy. International Journal of Cancer. https://doi.org/10.1002/ijc.32616
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.